Home

Ordering / Registration

FAQs

SIGN-IN /
REGISTER

The Resource for your Nonhuman Primate Research

We support innovation, reproducibility, and translation of preclinical research with high-quality biological development. We offer primate antibodies and recombinant proteins for pre-clinical NHP studies, NHP-specific reagents for in vitro assays, and have an industry wide antibody reactivity database for NHP species.

All Products

SEARCH IN:

All Products

Therapeutics (in Vivo)

Antibodies for Assays

Cells

Proteins

Reactivity Database

Recent Publications Using Our Reagents...

View All

NHPRR Product Catalog

Assay Reagent Catalog

New World Monkey Reagents

New World Spp (in vitro and in vivo)

NHPRR Therapeutics Catalog

Anti-Complement Antibodies
Anti-Cytokine/Chemokine and Receptors
Blocking Antibodies (Receptor-Ligand Antagonists)
Cell-Depleting Antibodies
Controls and Anti-Infectives
Fc-Fusion Proteins
Proteins & Enzymes
Serial Intravascular Staining (SIVS)
Stimulating Antibodies (Receptor-Ligand Agonists)

NHPRR News and Announcements

Follow the latest news on NHPRR's LinkedIn account and News Archives

NHP Reactivity

💬 Share your thoughts on a new chat-based tool for querying reagents 🚀

What questions would you want answered?

2026 January 02

Adjuvant IL-15 Blockade Significantly Improves Survival in a CD28-based Immunosuppression Protocol of Pig-to-nonhuman Primate Renal Xenotransplantation.

Keiler, James A Habib, Jakob G Han, Ji W Wilson, Bobbi J Guo, Lizheng Jenkins, Joe B Farris, A Brad Moore, Ian N Kitchens, William H Whitworth, Kristin M Adams, Andrew B Johnson, R Paul Larsen, Christian P Ford, Mandy L Kim, Steven C

Transplantation

Anti-IL-15 [ExNK] Anti-CD8 beta [CD8b255R1] Anti-CD4 [CD4R1]

2025 December 19

ALFQ adjuvanted HIV-1 envelope protein vaccination elicits durable functional antibody and cellular responses in nonhuman primates.

Shrivastava, Shikha Carmen, Joshua M Kim, Jiae Peachman, Kristina K Basu, Shraddha Alving, Ryan Nettere, Danielle Kundu, Gautam Yum, Lauren Rahman, Mohammad Arif Jha, Shalini Trinh, Hung V Rosado, Lorean Nguyen, Phuong Morrison, Elaine Swafford, Isabella Machmach, Kawthar Bolton, Jessica S Yates, Adam Misicka, Elina Beck, Zoltan Mutascio, Simona Jobe, Ousman Zemil McCrea, Michelle Wieczorek, Lindsay Bergmann-Leitner, Elke S Polonis, Victoria Paquin-Proulx, Dominic Pollara, Justin Matyas, Gary R Alving, Carl R Thomas, Rasmi Franchini, Genoveffa Ferrari, Guido Haynes, Barton F Ake, Julie A Rao, Mangala

NPJ Vaccines

Anti-rhesus IgG1/3 [1B3]-HRP Reference rhesus IgG1 (Anti-CD8a) [rIgG1] Reference rhesus IgG2 (Anti-CD8a) [rIgG2] Anti-rhesus IgG2 [dio]-HRP

2025 November 27

No change in key HIV target cell markers following initiation of three progestin-based hormonal contraception methods: findings from the CHIME study.

Young, Marisa R; Mehta, C Christina; Staple, Tyree; Herring, Gina Bailey; Govindaraj, Sakthivel; Ibegbu, Chris; Herold, Betsy C; Velu, Vijayakumar; Haddad, Lisa B; Smith, Alicia K

Frontiers in immunology

Anti-alpha4/beta7 [A4B7R1]-APC Anti-alpha4/beta7 [A4B7R1]-PE

2025 November 05

The TLR7 agonist vesatolimod does not measurably induce SIV expression in macaques receiving combination antiretroviral therapy initiated during chronic infection.

Swanstrom, Adrienne E Oswald, Kelli Fast, Randy Shoemaker, Rebecca Thomas, James A Pyle, Cathi Hull, Michael Bosche, William J Li, Yuan Breed, Matthew W Kramer, Joshua A Donohue, Duncan Trubey, Charles M Deleage, Claire Geleziunas, Romas Lifson, Jeffrey D Del Prete, Gregory Q

Antimicrob Agents Chemother

Anti-CD38 [OKT10]-PE

News & Updates:

View All

2024 Aug 23

mAbsolve Parnership for Fc-silenced STR Antibodies

Today, we celebrate a milestone—partnering with mAbsolve to incorporate ‘STR’ mutations into our antibodies. This ensures targeted action without unintended immune responses, boosting rigor, effectiveness, and safety. By decreasing Fc-mediated interference (hello Fc-block!) and enhancing the signal-to-noise ratio, STR-enhanced antibodies will produce more robust and reproducible scientific findings. Expect many STR-enhanced antibodies soon!

For your Acknowledgements section

Reagents used in these studies were provided by the NIH Nonhuman Primate Reagent Resource (P40 OD028116, U24 AI126683).

2024 Apr 11

NHPRR Linkedin

Follow our newest publications, products, and messages on LinkedIn!

RRID Citation on Materials and Methods

For your Materials & Methods section: The rhesus recombinant Anti-CD8 beta [CD8b255R1] monoclonal antibody was engineered and produced by the Nonhuman Primate Reagent Resource (NIH Nonhuman Primate Reagent Resource Cat# PR-2557, RRID:AB_2716321)

Anti-CD8 beta [CD8b255R1]

Contribute to the Resource

Help Us By:

Sharing Your Data: Our community-based reactivity database is built by users like you. Share your results!

Requesting a Reagent: We develop NHP-specific antibodies based on investigator-initiated requests, including: recombinant proteins for cell depletion, receptor activation, cytokine neutralization, co-stimulatory blockade, immunosuppression.

Licensing Our Reagents: Interested in using our antibodies on your assays? Reach us!

Sharing Your Publication: If you’ve recently published a study using an NHPRR reagent, add it to the publication database.

Share Your Data:

Now you can directly contribute your experimental data to our reactivity datatase. Send us your beautiful graphs and figures!

SHARE YOUR DATA

Request a Reagent:

Would you like to see an NHP-specific antibody developed through the program? Suggest a new reagent that would benefit the NHP community.

REQUEST A REAGENT

License Our Reagents:

We have species-specific reagents for preclinical studies in monkeys. Reach us if you are interested in learning about reagent partnerships.

LICENSE OUR REAGENTS

Share Your Publication:

We continue to grow the publication database so that peer-reviewed results can inform future research decisions.

SHARE YOUR PUBLICATION

The Nonhuman Primate Reagent Resource (NHPRR) is a nonprofit laboratory established in 1999, and supported by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), and Office of Research Infrastructure Programs (ORIP).